clinical pipeline with six regulatory approval submissions expected between
2009 and 2010. The Company's commercial strategy is to grow market share
for its currently marketed products using its sales and marketing
capabilities, acquire non-promoted or underperforming branded
pharmaceutical products and implement life cycle management techniques to
maximize the value of its currently marketed products, newly acquired
products and product candidates that are in development.
Safe Harbor Statement
Statements in this press release regarding benefits and synergies of
the merger; the progress and timing of product development programs and
related trials of the combined company; future opportunities for the
combined company; the strategy, future operations, financial position,
future revenues and projected costs of the combined company; prospects,
plans and objectives of the combined company's management; and any other
statements about management's future expectations, beliefs, goals, plans or
prospects constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995.
Any statements that are not statements of historical fact (including,
without limitation, statements containing the words 'believes,' 'plans,'
'could,' 'anticipates,' 'expects,' 'estimates,' 'plans,' 'should,'
'target,' 'will,' 'would' and similar expressions) should also be
considered to be forward-looking statements.
There are a number of important factors that could cause our actual
results or events to differ materially from those indicated by such
forward-looking statements, including: our ability to successfully
integrate the operations and employees of Critical Therapeutics and
Cornerstone BioPharma; our ability to realize anticipated synergies and
cost savings from the merger; our ability to develop and maintain the
necessary sales, marketing, distribution and manufacturing capabilities to
commercialize our produ
Page: 1 2 3 4 5 Related medicine news :1
|SOURCE Cornerstone BioPharma Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 252
. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team3
. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets4
. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference5
. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting6
. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG7
. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia8
. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association9
. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 200710
. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization11
. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development